Please read and agree to the terms and conditions of this site.
@xconomy.com 3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com 4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com 4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com 4 years ago
As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing
@xconomy.com 5 years ago
With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care
@xconomy.com 5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com 5 years ago
Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum
@xconomy.com 5 years ago
With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines
@xconomy.com 6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines